The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
The company received one observation in the Form-483
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
A triple-action Formula for comprehensive respiratory relief
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The company received one observation in the Form-483
The company received 1 (One) observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
